Ex­clu­sive: RA Cap­i­tal in­vests $35M in UK can­cer biotech Cell­Cen­tric

UK biotech Cell­Cen­tric is get­ting a $35 mil­lion boost from RA Cap­i­tal to fur­ther de­vel­op its mul­ti­ple myelo­ma pill.

The cap­i­tal in­fu­sion will help Cell­Cen­tric …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER